Intended for healthcare professionals


Update to living WHO guideline on drugs for covid-19

BMJ 2022; 377 doi: (Published 21 April 2022) Cite this as: BMJ 2022;377:o1005

This living guideline by Agarwal and colleagues (BMJ 2020;370:m3379) has been updated. For the latest update, visit doi:10.1136/bmj.m3379. The latest version of this WHO living guidance provides two new recommendations for patients with non-severe covid-19: (a) a strong recommendation for use of nirmatrelvir/ritonavir in patients at highest risk of hospitalisation; and a conditional recommendation against its use in patients at low risk of hospitalisation; (b) a conditional recommendation for use of remdesivir in patients at highest risk of hospitalisation.